Correspondence  by unknown
myocardial ischemia. Ideally, such proof should be obtained before the
patient is on the table for PTCA or surgery. Therefore, the first tools
to confirm reversible myocardial ischemia as the cause of chest pain
are noninvasive tests, of which exercise nuclear perfusion scintigraphy
is probably most widely used. This implicates that in a patient with
typical chest pain, a significant coronary artery stenosis, and a positive
nuclear test, it is not necessary at all to do invasive physiologic
assessment of that coronary lesion. In such cases, revascularization can
be performed straightforward.
However, in contrast to official guidelines, in many countries
(among which the USA) PTCA is performed in many patients without
documented proof of reversible schemia (1). In those cases, noninva-
sive tests were negative, not conclusive, or just not performed. In such
cases, in our opinion, it is mandatory to measure fractional flow reserve
to justify subsequent PTCA.
The clinical problem sketched above is especially pronounced in
case of intermediate stenosis or in patients with atypical chest pain. It
is well known that in such patients, if they persist to complain, coronary
angiography is often performed despite negative (nuclear) stress
testing and that merely the visible presence of a stenosis in those cases
triggers coronary intervention (oculo-stenotic reflex). Such a problem
was present in the majority of the patient population described in our
recent paper (2).
In the remaining 28 patients, a positive regular exercise test was
present. In those cases coronary pressure measurements were per-
formed because of the discrepancy between the positive exercise test
and either the chest pain or the moderate severity of the coronary
artery stenosis. We have argued that in such a population the incidence
of false-positive exercise testing is rather high, and the favorable
outcome of our patients after deferral of a PTCA supports that
position. If in all these patients nuclear scintigraphy had been per-
formed, probably many of these tests would have been (true) negative
because of the higher specificity of nuclear exercise testing compared
with exercise testing alone. It should be kept in mind, however, that
especially in the case of intermediate stenosis, the accuracy of nuclear
stress testing is not as high as desirable, as shown in our recent paper
in the New England Journal of Medicine (3). In that paper it was shown
that the diagnostic accuracy of invasive FFR determination was as high
as the combined accuracy of exercise testing, nuclear scintigraphy, and
stress-echo and higher than that of any noninvasive single test if
performed alone.
In conclusion, we acknowledge the great value of nuclear stress
testing for noninvasive assessment of coronary artery disease and
emphasize that—with very few exceptions—objective evidence of
reversible ischemia should be documented in any way before perform-
ing a revascularization procedure.
However, if that has not been done, as is often the case, or if the
results of noninvasive tests are not conclusive or contrasting to other
clinical data, justification of performing a PTCA on one hand or
deferring the PTCA on the other hand can be found by measuring
coronary pressure and fractional flow reserve just prior to the planned
intervention.
NICO H. J. PIJLS, MD, PhD
Department of Cardiology
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Familial Dilated Cardiomyopathy
Gru¨nig et al. (1) have reported the results of their detailed examina-
tion of a large number of relatives of probands with dilated cardiomy-
opathy (DCM) and have concluded that up to 35% of patients with
DCM may have an inherited disorder. Their work makes a valuable
contribution to the area of inherited cardiac disease and emphasises
the need for careful history taking and assessment of relatives in cases
where the disease may, otherwise, appear to be sporadic in nature.
However, there are several points that need to be addressed.
First, they report a family history and pedigree analysis negative for
familial DCM in 289 of the 445 index patients. However, in this group,
only 231 family members were examined—this means that in at least
58 cases familial disease cannot be definitely excluded and it would
have been more appropriate to classify these as indeterminate rather
than negative. Second, the definition of “suspected” DCM is rather
loose and thereby creates the potential for mis-classification of familial
disease. Third, the classification of the familial cases into six groups
based on characteristic features and prognosis is helpful in defining
patterns of disease. However, the authors do not attempt to address
the issue of autosomal recessive disease (2).
Fourth, the description of the phenotype (from A to F) changes
between Table 2 and Tables 3/4. Fifth, the inference from Table 2 is
that all cases of phenotype A are caused by mutations in the dystrophin
gene but, on perusal of the text, this has been validated for only one
family.
Finally, there are numerous instances where the numbers quoted in
the table do not agree with the text and careful examination of the
pedigrees also reveals some discrepancies.
1. Figure 1: the number of cases classified as “suspected familial
DCM” should read n 5 108 (not n 5 110).
2. Table 1: in the section under “functional status” the numbers
under “course,” “transplantation,” and “death” do
not add up correctly—are the groups mutually exclu-
sive? The data set under “X-ray findings” is incom-
plete but no explanation is offered in the text.
3. Page 188: the numbers in the text “On examination, concomi-
tant cardiac abnormalities, such as unspecific ECG
changes. . . . ” do not add up to 120.
4. Table 3: the numbers in the section “functional status at
diagnosis” do not add up correctly—no explanation is
given in the text to account for missing data.
5. Figure 2: according to my interpretation of the pedigree IV-12
is the cousin and not the nephew of the index case
IV-16. Three females are classified as affected but the
text on page 189 reports depressed LV function in
only two cases. This also leads on to difficulty with the
numbers reported in Table 3 under Phenotype A.
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5. Figure 5: there are some inconsistencies in recording the death
of affected case III-10.
6. Phenotype D (on page 191): “In all 20 patients, either atrial
fibrillation (n 5 14) or AV block (n 5 7) was
documented. . . . ” Again the numbers do not add up
correctly. Should the text read ‘atrial fibrillation
and/or AV block’?
PASCAL MCKEOWN, MD
Regional Medical Cardiology Centre
Royal Victoria Hospital
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Reply
We thank Dr. McKeown for his supportive and critical comments
concerning our recently published manuscript. Our paper summarizes
a 5-year effort to elucidate the frequency and clinical phenotypes of
familial disease in 445 index patients with invasively documented
dilated cardiomyopathy (DCM). We could show that familial aggre-
gation of the disease is possibly present in 35% of all index patients.
These findings indicate the need for a careful history taking in patients
with DCM. As with any work that attempts to analyze the families of
445 index patients some important points cannot be addressed in a
depth due to limitations in time and manpower.
Thus, we agree that in 58 cases familial disease could not be
excluded definitely since we were not able to investigate the family
members for presence of dilated cardiomyopathy by clinical examina-
tion, ECG-recording, and cardiac ultrasound. Thus, indeed it may be
possible that the prevalence of familial disease may have been even
higher than reported. However, we have commented on this limitation
and thus had hoped that this limitation is apparent to the reader.
We also agree, that the definition of suspected DCM is rather
loose. However we felt: a) that the wording of “suspected” implies a
residual uncertainty, and b) that the diagnosis suspected DCM is still
a valid information, considering the difficulties of proper clinical
classification of the presence of absence of DCM.
Our intention was to emphasize that patients with familial DCM
may represent with different phenotypes, which are important for
diagnostic classification and for further risk stratification of the
patients and may be helpful for genetic analysis. The issue of potential
autosomal recessive disease was not explicitly addressed because an
autosomal recessive way of inheritance was not certainly observed in
our study and may indeed be very rare (2,3).
Table 1 summarizes the clinical definitions of phenotypes and their
possible genetic causes, whereas table 3 and 4 classify clinical findings
of the examined families. We agree that a more uniform presentation
may have facilitated the reading of the tables.
The major clinical difference between group A and B was that of an
elevation of creatine kinase activity in serum in group A patients. The
elevation of CK activity in blood was taken as evidence for the
involvement of skeletal muscle disease, which is a common finding in
patients with mutations of the dystrophin molecule. Indeed, we were
able to identify a dystrophin mutation in one of the two families. This
certainly is no proof that all cases of CK positive DCM may be caused
by dystrophin mutations. However, it is likely that dystrophin muta-
tions may also have been present in the second family.
We furthermore appreciate the detailed correction of typographi-
cal errors, although they do not pertain to any of the results or any of
the conclusions made in this study: Figure 1 n 5 108 instead of 110 and
Figure 5 III-10 n/ instead of n1. On page 191, “and/or” may indeed be
better than “or.” It is correct, that patient IV12 in Figure 2 should read
as cousin and not as nephew. Finally, it was not possible to give a
functional status in individuals diagnosed as DCM by autopsy, leading
to the erroneous conclusion of “missing data” in Table 3.
HUGO A. KATUS, MD, EKKEHARD GRU¨NIG, MD
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